ライフサイエンスコーパス: pyrimethamine

1 er resistance to chloroquine and sulfadoxine-pyrimethamine.

2 ittent preventive treatment with sulfadoxine-pyrimethamine.

3 s: mefloquine, chloroquine, doxycycline, and pyrimethamine.

4 on cassette were retrieved by selection with pyrimethamine.

5 unate-amodiaquine or amodiaquine-sulfadoxine-pyrimethamine.

6 sed efficacy of amodiaquine plus sulfadoxine-pyrimethamine.

7 hydrophobic antifols such as trimetrexate or pyrimethamine.

8 dose of 1500 mg of sulfadoxine and 75 mg of pyrimethamine.

9 uch as chloroquine, quinine, and sulfadoxine-pyrimethamine.

10 enotype and clinical or in vitro response to pyrimethamine.

11 modiaquine, or amodiaquine plus sulphadoxine-pyrimethamine.

12 7 participants assigned to sulfadoxine\#8211;pyrimethamine.

13 its for birth outcomes than does sulfadoxine-pyrimethamine.

14 50 concentrations of mefloquine, quinine and pyrimethamine.

15 ioration of the effectiveness of sulfadoxine-pyrimethamine.

16 piperaquine as an alternative to sulfadoxine-pyrimethamine.

17 in birth outcomes compared with sulfadoxine-pyrimethamine.

18 ely reduced by an anti-STAT3 treatment using pyrimethamine.

19 nation therapy, chloroquine, and sulfadoxine-pyrimethamine.

20 in blocks of 16 to sulfadoxine (250 mg) plus pyrimethamine (12.5 mg; n=319 in moderate-transmission a

21 125 [35%]) than with amodiaquine+sulfadoxine-pyrimethamine (12/129 [9%]; risk difference 26% [95% CI

22 ent over 28 days for amodiaquine+sulfadoxine-pyrimethamine (17/129 [13%]) and amodiaquine+artesunate

23 1.1%-32.1%) for amodiaquine plus sulfadoxine-pyrimethamine, 17.4% (95% CI, 13.1%-23.1%) for amodiaqui

24 quine (25 mg/kg over 3 days) and sulfadoxine-pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimeth

25 ficantly higher with chloroquine+sulfadoxine-pyrimethamine (44/125 [35%]) than with amodiaquine+sulfa

26 mine (90%) than those receiving sulphadoxine-pyrimethamine (48%) or no antimalarial drugs (34%; p<0.0

27 In order to identify structural features of pyrimethamine (5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-

28 97 of 476 (20%) for amodiaquine+sulfadoxine-pyrimethamine, 54 of 491 (11%) for amodiaquine+artesunat

29 ts aged 2-11 months, but neither sulfadoxine-pyrimethamine (-6.7%, -45.9 to 22.0) nor chlorproguanil-

30 ger antimalarial effect than did sulfadoxine-pyrimethamine (8 g, -9 to 26), although more frequent do

31 quine (86%) or amodiaquine plus sulphadoxine-pyrimethamine (90%) than those receiving sulphadoxine-py

32 When used in combination with pyrimethamine, a DHFR inhibitor, a synergistic effect wa

33 -dapsone was less effective than sulfadoxine-pyrimethamine (adjusted odds ratio [OR], 6.4; 95% confid

34 36-66, p<0.0001) compared with sulfadoxine/ pyrimethamine alone and by 37% (12-54, p=0.007) compared

35 ne alone or in combination with sulphadoxine-pyrimethamine, although associated with minor side-effec

36 tion therapies (amodiaquine plus sulfadoxine-pyrimethamine, amodiaquine plus artesunate, or artemethe

37 We compared chloroquine+sulfadoxine-pyrimethamine, amodiaquine+sulfadoxine-pyrimethamine, an

38 the women assigned chloroquine, sulphadoxine-pyrimethamine, amodiaquine, and amodiaquine plus sulphad

39 Sulfadoxine/pyrimethamine, amodiaquine, and amodiaquine/sulfadoxine/

40 randomly assigned chloroquine, sulphadoxine-pyrimethamine, amodiaquine, or amodiaquine plus sulphado

41 in areas with high resistance to sulfadoxine-pyrimethamine among P falciparum parasites, but remains

42 cation with treatment studies of sulfadoxine-pyrimethamine among symptomatic children.

43 fected cells with the toxoplasmastatic drugs pyrimethamine and 6-thioxanthine prior to LPS stimulatio

44 dy a high level of resistance to sulfadoxine-pyrimethamine and amodiaquine.

45 high prevalence of resistance to sulfadoxine-pyrimethamine and chloroquine.

46 ind, placebo-controlled trial of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment for u

47 get of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of

48 e reductase (DHFR) to two related inhibitors-pyrimethamine and cycloguanil-across a breadth of drug c

49 with either chloroquine or sulfadoxine\#8211;pyrimethamine and followed for 28 days to assess the ant

50 susceptibly to the non-classical antifolates pyrimethamine and nolatrexed.

51 imalarials, such as Chloroquine, Sulfadoxine-Pyrimethamine and oral Artesunate monotherapy.

52 ed until delivery with regular monitoring of pyrimethamine and sulfadiazine concentration in maternal

53 groups preferring to use the combination of pyrimethamine and sulfadiazine.

54 and dhps genes respectively associated with pyrimethamine and sulfadoxine resistance.

55 teroate synthase (DHPS) confer resistance to pyrimethamine and sulfadoxine, respectively.

56 ions in enzymes targeted by the antifolates, pyrimethamine and sulphadoxine.

57 oses of the clinical antimalarial inhibitors pyrimethamine and tetracycline and observed differential

58 tive treatment with two doses of sulfadoxine-pyrimethamine and the use of insecticide-treated nets.

59 um parasitemia were treated with sulfadoxine-pyrimethamine and were monitored for 28 days.

60 intermittent preventive therapy (sulfadoxine-pyrimethamine) and insecticide-treated mosquito nets are

61 oxine-pyrimethamine, amodiaquine+sulfadoxine-pyrimethamine, and amodiaquine+artesunate for treatment

62 led trial comparing chloroquine, sulfadoxine-pyrimethamine, and chlorproguanil-dapsone for the treatm

63 ne than among those who received sulfadoxine-pyrimethamine, and monthly treatment with dihydroartemis

64 ve pharmaceutical ingredients, sulfalene and pyrimethamine, and NQR analysis revealed spectral differ

65 Furthermore, albendazole, pyrimethamine, and penicillin demonstrate that generic m

66 axis with the combination of sulfadoxine and pyrimethamine, and treatment, as needed.

67 IPTp with sulfadoxine-pyrimethamine appears to have potent non-malarial effect

68 ries of resistance: chloroquine, sulfadoxine-pyrimethamine, artemisinin, and piperaquine.

69 ne alone or in combination with sulphadoxine-pyrimethamine as alternative regimens.

70 n, we identified the anti-parasitic compound pyrimethamine as an inhibitor of STAT3 function.

71 ed as a potential alternative to sulfadoxine-pyrimethamine as intermittent preventive treatment again

72 Artesunate-sulfadoxine-pyrimethamine (ASSP) is the frontline artemisinin combin

73 in an area of high resistance to sulfadoxine-pyrimethamine at sites of moderate (n=1280 infants enrol

74 Administration of sulfadoxine-pyrimethamine at times of vaccination-intermittent preve

75 was a near-significant risk elevation after pyrimethamine/azithromycin treatment (P = .078 and P = .

76 e demonstrated superior efficacy compared to Pyrimethamine based counterparts in an in vivo model of

77 In contrast, inhibition of MATE1 with pyrimethamine caused accumulation of metformin in the li

78 es of women randomly assigned to sulfadoxine-pyrimethamine compared with women assigned to dihydroart

79 Mediation analyses showed sulfadoxine-pyrimethamine conferred a greater non-malarial effect th

80 Treatment with pyrimethamine decreases cell proliferation in human ADPK

81 IPTi with sulfadoxine-pyrimethamine did not have a clinically significant effe

82 INTERPRETATION: IPTi with sulfadoxine-pyrimethamine does not affect serological responses to E

83 Nine trials of IPT with sulfadoxine-pyrimethamine during pregnancy in Africa were identified

84 red 2-dose with monthly IPT with sulfadoxine-pyrimethamine during pregnancy.

85 egnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months in children

86 om two doses to monthly doses of sulfadoxine-pyrimethamine during the second and third trimesters, bu

87 uail eggs were found to contain florfenicol, pyrimethamine, estrone and 17beta-estradiol at levels fr

88 in which 1 of 4 treatments with sulfadoxine-pyrimethamine fail in children by day 14, the 2-dose IPT

89 re treated with amodiaquine plus sulfadoxine-pyrimethamine for 396 episodes of uncomplicated malaria

90 sing alternative drug to replace sulfadoxine-pyrimethamine for intermittent preventive treatment.

91 uine with the combination of sulfadoxine and pyrimethamine for the treatment of malaria.

92 da were treated with amodiaquine+sulfadoxine-pyrimethamine for uncomplicated malaria.

93 ittent preventive treatment with sulfadoxine-pyrimethamine group (15 [3%] of 457 women vs 47 [10%] of

94 raquine group (9.2%) than in the sulfadoxine-pyrimethamine group (18.6%, P=0.05) or the three-dose di

95 gnificantly more frequent in the sulfadoxine/pyrimethamine group (38 of 215, 18%) compared with eithe

96 was significantly higher in the sulfadoxine-pyrimethamine group (41 episodes over 43.0 person-years

97 was significantly higher in the sulfadoxine-pyrimethamine group (50.0%) than in the three-dose dihyd

98 hange 13 ms [SD 23]) than in the sulfadoxine-pyrimethamine group (mean change 0 ms [SD 23]; p<0.0001)

99 By day 14, only 1 patient in the sulfadoxine-pyrimethamine group had parasites.

100 nce of parasitemia (40.5% in the sulfadoxine-pyrimethamine group vs. 16.6% in the three-dose dihydroa

101 5 of 290 patients (1.7%) in the sulfadoxine-pyrimethamine group, and 27 of 272 patients (9.9%) in th

102 , even in eastern and southern Africa, where pyrimethamine has been intensively used.

103 Sulfadoxine-pyrimethamine has been widely used as first-line therapy

104 IPTi with sulfadoxine-pyrimethamine has no benefit in areas of very high resis

105 ce to the antifolate combination sulfadoxine-pyrimethamine have a common origin.

106 Antifolate antimalarials, such as pyrimethamine, have experienced a dramatic reduction in

107 randomly assigned to treatment (sulfadoxine-pyrimethamine in combination with amodiaquine or dual pl

108 and susceptible parasites are exacerbated by pyrimethamine in mice.

109 finity)) or the half-lives of sulfadoxine or pyrimethamine in prepartum or postpartum women, although

110 ittent preventive treatment with sulfadoxine-pyrimethamine in the context of high sulfadoxine-pyrimet

111 preventive treatment (IPT) with sulphadoxine-pyrimethamine in vulnerable populations reduces malaria

112 ia prevention (ITNs or IPTp with sulfadoxine-pyrimethamine) in pregnancy and birth outcomes, includin

113 individuals (934 placebo and 970 sulfadoxine-pyrimethamine) in the study.

114 effectiveness of daily CMX with sulfadoxine-pyrimethamine intermittent preventive treatment (IPT-SP)

115 ittent preventive treatment with sulfadoxine-pyrimethamine, intermittent preventive treatment with di

116 Therapeutic alternatives to sulfadoxine-pyrimethamine IPTp are needed in areas where the prevale

117 (primary outcome) and malaria by sulfadoxine-pyrimethamine IPTp dose, and for studies that reported o

118 ciparum and the effectiveness of sulfadoxine-pyrimethamine IPTp for malaria-associated outcomes.

119 The effectiveness of sulfadoxine-pyrimethamine IPTp is reduced in areas with high resista

120 from 13 surveys (42 394 births), sulfadoxine-pyrimethamine IPTp was associated with reduced prevalenc

121 ittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) during pregnancy.

122 eventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of efforts in su

123 tive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) would improve maternal and infan

124 ttent preventative therapy with sulphadoxine-pyrimethamine (IPTp-SP).

125 tive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP).

126 ittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP).

127 ttent-preventive-treatment with sulphadoxine-pyrimethamine (IPTp-SP).

128 ttent preventive treatment using sulfadoxine-pyrimethamine (IPTp-SP).

129 entive therapy in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP).

130 (IPTp-SP3+) versus two doses of sulfadoxine-pyrimethamine (IPTp-SP2).

131 ciparum to the antimalarial drug sulfadoxine-pyrimethamine is a result of extremely rare mutations th

132 Pyrimethamine is capable of producing a significant redu

133 The target enzyme of pyrimethamine is dihydrofolate reductase (DHFR), but lit

134 Increasing resistance to sulfadoxine-pyrimethamine is leading to a decline in its effectivene

135 Resistance to sulfadoxine-pyrimethamine is now increasing, especially in southeast

136 INTERPRETATION: Pyrimethamine is safe and well tolerated in ALS.

137 Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention o

138 This study investigated whether pyrimethamine lowered SOD1 levels in the cerebrospinal f

139 A previous phase 1 trial showed pyrimethamine lowers SOD1 levels in leukocytes in patien

140 ) in areas of high resistance to sulfadoxine-pyrimethamine (Lys540Glu >=90% in east and southern Afri

141 We propose that clinical dosages of pyrimethamine may have historically been too low to sele

142 ve therapy during pregnancy with sulfadoxine-pyrimethamine monotherapy.

143 Compared with monthly doses of sulfadoxine-pyrimethamine, monthly doses of dihydroartemisinin-piper

144 and randomly assigned to receive sulfadoxine-pyrimethamine (n=391) or dihydroartemisinin-piperaquine

145 modiaquine (n=270), amodiaquine +sulfadoxine-pyrimethamine (n=507), or amodiaquine+artesunate (n=515)

146 ittent preventive treatment with sulfadoxine-pyrimethamine (n=515); 1368 (88%) women comprised the in

147 ntry to replace chloroquine with sulfadoxine-pyrimethamine nationwide in response to high rates of ch

148 with the spread of resistance to sulfadoxine-pyrimethamine, new interventions are needed.

149 Data on the efficacy of IPT with sulfadoxine-pyrimethamine on placental and peripheral malaria, birth

150 fect of increasing resistance to sulfadoxine-pyrimethamine on the efficacy of IPT during pregnancy in

151 Combinations of amodiaquine and sulfadoxine-pyrimethamine or artesunate were significantly more effi

152 xual parasites more rapidly than sulfadoxine-pyrimethamine or chlorproguanil-dapsone did.

153 reatment as random assignment to sulfadoxine-pyrimethamine or dihydroartemisinin-piperaquine before p

154 treatment during pregnancy with sulfadoxine-pyrimethamine or dihydroartemisinin-piperaquine.

155 e combination of chloroquine and sulfadoxine-pyrimethamine or fosmidomycin may be more effective agai

156 e investigated whether IPTi with sulfadoxine-pyrimethamine or other antimalarial drug combinations ad

157 f an adverse effect of IPTi with sulfadoxine-pyrimethamine or other antimalarial drugs on the proport

158 nd 15, respectively) than in the sulfadoxine-pyrimethamine or placebo groups (eight deaths per group;

159 STAT3 and that blocking STAT3 signaling with pyrimethamine or similar drugs may be an attractive ther

160 e of artesunate plus one dose of sulfadoxine-pyrimethamine or two placebos on three occasions during

161 ydroartemisinin-piperaquine with sulfadoxine-pyrimethamine (or another compound with non-malarial eff

162 quine (25 mg/kg over 3 days) and sulfadoxine-pyrimethamine; or amodiaquine and artesunate (4 mg/kg da

163 Unlike pyrimethamine, P218 binds both wild-type and mutant PfDH

164 us did not show any significant influence on pyrimethamine pharmacokinetics.

165 mefloquine-artesunate (MQAS) or sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) was more effective

166 Sulfadoxine/pyrimethamine plus amodiaquine could be used as an inexp

167 d the effectiveness of SMC using sulfadoxine-pyrimethamine plus amodiaquine given over 5 months to ch

168 5, 18%) compared with either the sulfadoxine/pyrimethamine plus amodiaquine group (two of 164, 1%; p<

169 28 and 42 days, patients in the sulfadoxine/pyrimethamine plus amodiaquine group were significantly

170 Overall, sulfadoxine/pyrimethamine plus amodiaquine reduced the rate of subse

171 n of azithromycin to the monthly sulfadoxine-pyrimethamine plus amodiaquine used for seasonal malaria

172 omycin or placebo, together with sulfadoxine-pyrimethamine plus amodiaquine, during the annual malari

173 up (two of 164, 1%; p<0.0001) or sulfadoxine/pyrimethamine plus artesunate group (one of 198, 1%; p<0

174 ng monthly chemoprophylaxis with sulfadoxine-pyrimethamine plus artesunate to selectively control tim

175 % (12-54, p=0.007) compared with sulfadoxine/pyrimethamine plus artesunate.

176 receive 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine plus either placebo, 25 mg/kg amodiaquine,

177 Pyrimethamine produces dose-dependent SOD1 reduction in

178 ntion (SMC) with amodiaquine and sulfadoxine-pyrimethamine provides substantial benefit to this vulne

179 aimiri boliviensis monkeys infected with the pyrimethamine (Pyr)-susceptible Chesson strain with a ZF

180 proved parasite clearance when combined with Pyrimethamine (Pyr).

181 Intermittent treatment with sulfadoxine-pyrimethamine, recommended for prevention of malaria in

182 domly assigned participants to a sulfadoxine-pyrimethamine regimen (106 participants), a three-dose d

183 n by day 14, the 2-dose IPT with sulfadoxine-pyrimethamine regimen continues to provide substantial b

184 the chloroquine related crt and sulfadoxine-pyrimethamine related dhfr.

185 onsistent across a wide range of sulfadoxine-pyrimethamine resistance (0% to 96% dihydropteroate-synt

186 explore the modifying effects of sulfadoxine-pyrimethamine resistance (as indicated by Ala437Gly, Lys

187 methamine in the context of high sulfadoxine-pyrimethamine resistance and malaria transmission.

188 hich has experienced sustained selection for pyrimethamine resistance at the dihydrofolate reductase

189 Increasing sulfadoxine-pyrimethamine resistance in Africa threatens current pre

190 The spread of high-level pyrimethamine resistance in Africa threatens to curtail

191 We report that increases in gch1 CN alter pyrimethamine resistance in most parasites lines.

192 associations between markers of sulfadoxine-pyrimethamine resistance in P falciparum and the effecti

193 Pyrimethamine resistance in the malaria parasite Plasmod

194 This allele also conferred high levels of pyrimethamine resistance in vitro.

195 scents or women in Uganda, where sulfadoxine-pyrimethamine resistance is widespread.

196 The effect did not vary by sulfadoxine-pyrimethamine resistance levels (range, 19%-26%).

197 ng that malaria parasites bearing high-level pyrimethamine resistance originally arrived in Africa fr

198 h ACT along with predominance of sulfadoxine-pyrimethamine resistance parasite invoked a strong possi

199 CI, 19-205 g) over the range of sulfadoxine-pyrimethamine resistance tested (8%-39%).

200 le evolutionary pathways in the evolution of pyrimethamine resistance using an approach in which all

201 Sulfadoxine-pyrimethamine resistance was defined as the proportion o

202 The movement by the dhfr alleles (pyrimethamine resistance) preceded that of the dhps alle

203 ttings with different underlying sulfadoxine-pyrimethamine resistance.

204 th high malaria transmission and sulfadoxine-pyrimethamine resistance.

205 gh malaria transmission and high sulfadoxine-pyrimethamine resistance.

206 pecially for locations with high sulfadoxine-pyrimethamine resistance.

207 e simulated realizations of the evolution of pyrimethamine resistance.

208 reported on molecular markers of sulfadoxine-pyrimethamine resistance.

209 th high malaria transmission and sulfadoxine-pyrimethamine resistance.

210 4 key amino acid replacements implicated in pyrimethamine resistance: N51I, C59R, S108N, and I164L.

211 In order to directly assess the costs of pyrimethamine-resistance in vivo, we have carried out co

212 d in vivo, which may explain why this highly pyrimethamine-resistant allele has not been observed in

213 t-expression system to identify rare, highly pyrimethamine-resistant alleles of dhfr in isolates from

214 rocytic development of both chloroquine- and pyrimethamine-resistant P. falciparum strains with poten

215 kb region with extremely low polymorphism in pyrimethamine-resistant parasites.

216 Molecular assays for monitoring sulfadoxine-pyrimethamine-resistant Plasmodium falciparum have not b

217 odiaquine, and amodiaquine plus sulphadoxine-pyrimethamine, respectively (p<0.0001).

218 cific alleles and the failure of sulfadoxine/pyrimethamine (S/P) to clear the erythrocytic stages of

219 ased risk of clinical failure of sulfadoxine-pyrimethamine (S/P).

220 e if changes in gch1 expression alone modify pyrimethamine sensitivity, we manipulated gch1 CN in sev

221 quine with the standard of care, sulfadoxine-pyrimethamine, showed dihydroartemisinin-piperaquine was

222 We aimed to assess whether sulfadoxine-pyrimethamine shows greater non-malarial benefits for bi

223 imethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine, single dose); amodiaquine (25 mg/kg over

224 eated with chloroquine (CQ) plus sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) plus SP were tes

225 requency of molecular markers of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) resistance did n

226 atment (IPTp) with two doses of sulphadoxine-pyrimethamine (SP) and insecticide-treated-nets (ITNs) i

227 ttent preventive treatment with sulphadoxine-pyrimethamine (SP) and SP plus azithromycin (SPAZ) reduc

228 ficacy of this drug with that of sulfadoxine-pyrimethamine (SP) as treatment for uncomplicated falcip

229 (IPTi) is the administration of sulfadoxine-pyrimethamine (SP) at 2, 3, and 9 months of age to preve

230 ent during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) decreases placental malaria parasitem

231 tudied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 treatments am

232 However, sulfadoxine-pyrimethamine (SP) efficacy is threatened by high-level

233 istance to the antimalarial drug sulfadoxine-pyrimethamine (SP) emerged in Plasmodium falciparum from

234 anization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment

235 sites resistant to the IPTp drug sulfadoxine-pyrimethamine (SP) have emerged worldwide, and infection

236 loquine (MQ) compared with IPTp-sulphadoxine-pyrimethamine (SP) in human immunodeficiency virus (HIV)

237 malaria in pregnancy (IPT) with sulfadoxine-pyrimethamine (SP) in Malawi, the impacts of IST-DP and

238 piperaquine (DP) was superior to sulfadoxine-pyrimethamine (SP) in preventing maternal and placental

239 s paired with artesunate (AS) or sulfadoxine-pyrimethamine (SP) in recommended antimalarial regimens.

240 Pfdhfr and Pfdhps have rendered sulfadoxine-pyrimethamine (SP) ineffective for malaria treatment in

241 otrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp

242 ugs such as chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) is a major global health threat.

243 Sulfadoxine-pyrimethamine (SP) is among the most commonly used antim

244 ent during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is protective against malaria but may

245 eatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for malaria prevention

246 Sulfadoxine-pyrimethamine (SP) is used as intermittent preventive th

247 Sulfadoxine-pyrimethamine (SP) is used throughout Africa for intermi

248 ts and received a single dose of sulfadoxine-pyrimethamine (SP) on enrollment, followed by either int

249 laria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), given each mon

250 Tp comparing the standard 2-dose sulfadoxine-pyrimethamine (SP) regimen with monthly IPTp among a coh

251 ciated with chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) resistance and the microsatellite loc

252 Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan Africa, mon

253 In 2007, Malawi replaced sulfadoxine-pyrimethamine (SP) with an artemisinin-based combination

254 e to no chemoprevention, monthly sulfadoxine-pyrimethamine (SP), daily trimethoprim-sulfamethoxazole

255 lm of blood and was treated with sulfadoxine/pyrimethamine (SP), in accordance with national policy.

256 d for uncomplicated malaria with sulfadoxine-pyrimethamine (SP), SP + amodiaquine (AQ), or SP + artes

257 malarial parasite resistance to sulfadoxine-pyrimethamine (SP), SP continues to be recommended for i

258 lacebo, artemether-lumefantrine, sulfadoxine-pyrimethamine (SP), SP+amodiaquine, SP+piperaquine, SP+c

259 to concerns about resistance to sulphadoxine-pyrimethamine (SP), the only drug currently recommended

260 times inadvertently treated with sulfadoxine-pyrimethamine (SP).

261 g simultaneous administration of sulfadoxine-pyrimethamine (SP-IPTi) with immunizations, we measured

262 By contrast, resistance to sulphadoxine-pyrimethamine (SPR) has emerged during an era of molecul

263 ittent preventive treatment with sulfadoxine-pyrimethamine strategy recommended by WHO is threatened

264 In a control sulfadoxine-pyrimethamine study, the prevalence of ms4760-1 was simi

265 he pregnant woman until week 16, followed by pyrimethamine, sulfadiazine, and folinic acid for at lea

266 at least 4 weeks of combination therapy with pyrimethamine, sulfadiazine, and folinic acid independen

267 efficacy of chloroquine, and the combination pyrimethamine-sulfadoxine is the most commonly chosen al

268 ed the synergy of the antifolate combination pyrimethamine/sulfadoxine.

269 ich enabled teachers to dispense sulfadoxine-pyrimethamine tablets according to national guidelines.

270 ance of Plasmodium falciparum to sulfadoxine-pyrimethamine threatens the antimalarial effectiveness o

271 m falciparum to chloroquine and sulphadoxine-pyrimethamine threatens the use of these drugs for malar

272 Compared with three doses of sulfadoxine-pyrimethamine, three doses of dihydroartemisinin-piperaq

273 trials compared 2-dose IPT with sulfadoxine-pyrimethamine to case management or placebo in women dur

274 rmittent preventive therapy with sulfadoxine-pyrimethamine to control malaria during pregnancy is use

275 or coadministration of IPTi with sulfadoxine-pyrimethamine to infants at the time of the second and t

276 aken to determine the safety and efficacy of pyrimethamine to lower SOD1 levels in the CSF in fALS/SO

277 ttent preventive treatment with sulphadoxine-pyrimethamine to pregnant women (IPTp-SP) through antena

278 e was no evidence of transcript induction in pyrimethamine-treated parasites.

279 le mutant") were associated with sulfadoxine-pyrimethamine treatment failure but not with chlorprogua

280 hydroartemisinin-piperaquine and sulfadoxine-pyrimethamine treatment group (54 [16%] of 337 women vs

281 in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and monthly amodia

282 ded among factors that determine sulfadoxine-pyrimethamine treatment outcome.

283 associated with chloroquine or sulphadoxine-pyrimethamine treatment, attention has turned to the few

284 HIV infection on the response to sulfadoxine-pyrimethamine treatment.

285 100), and the efficacy of sulfadoxine\#8211;pyrimethamine was 21% (95% CI, 13 to 30).

286 therapy with 3 or more doses of sulfadoxine-pyrimethamine was associated with a higher birth weight

287 eatment failure with amodiaquine+sulfadoxine-pyrimethamine was balanced by a lower risk of new infect

288 m 2368 children from sites where sulfadoxine-pyrimethamine was compared with placebo were analysed fo

289 Sulfadoxine-pyrimethamine was first introduced for treatment of mala

290 ated with clinical resistance to sulfadoxine-pyrimethamine was found in 0.8% of samples from malaria

291 Efficacy of IPT with sulfadoxine-pyrimethamine was lower among women using insecticide-tr

292 Pyrimethamine was measured in plasma and CSF.

293 minant of treatment outcome with sulfadoxine-pyrimethamine was retrospectively studied in young child

294 eatment failure with chloroquine+sulfadoxine-pyrimethamine was unacceptably high.

295 ne, amodiaquine, and amodiaquine/sulfadoxine/pyrimethamine were all effective for treatment of uncomp

296 The pharmacokinetics of sulfadoxine and pyrimethamine were compared between these groups.

297 Chloroquine and sulfadoxine-pyrimethamine were equivalent in efficacy at day 28 (adj

298 blinded clinical trial comparing sulfadoxine-pyrimethamine with mefloquine IPTp.

299 ly the most effective, is the combination of pyrimethamine with sulfadiazine and folinic acid.

300 Treatment with lower and higher doses of pyrimethamine with sulfadizine improved outcomes relativ